A CHOP oncologist co-led an international study showing that an abnormal fused gene drives children’s brain tumors by using three different biological mechanisms. 

After children with leukemia receive chemotherapy, are they better off remaining in the hospital, or going home? CHOP is leading a multicenter study of both safety and family preferences.

CHOP’s new Center for Data Driven Discovery in Biomedicine aims to harness and broadly share biomedical information to more quickly benefit child patients. 

CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.

A $1.5 million grant to CHOP from Alex’s Lemonade Stand Foundation supports an innovative treatment for children with high-risk neuroblastoma.

CHOP’s Dr. John Maris comments on a just-published major study of genes that raise a child’s risk for cancer, and what this means for counseling families and patients.

CHOP pediatric oncology researchers have pinpointed a crucial change in a single DNA “letter” that predisposes children to an aggressive form of neuroblastoma.

The Four Seasons Parkway Run & Walk raised over $1 million and proceeds support research and survivorship programs at CHOP’s Cancer Center.

Building on its decades-long investigations in the biology and treatment of neuroblastoma, CHOP will lead the consortium’s neuroblastoma research program. 

CHOP neuroblastoma researchers have detailed how cancer-driving mutations evolve during chemotherapy, and they aim to exploit this knowledge to design better treatments for children.